This HTML5 document contains 154 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n21http://linked.opendata.cz/resource/drugbank/drug/DB00804/identifier/bindingdb/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00804/identifier/kegg-compound/
n2http://linked.opendata.cz/resource/drugbank/drug/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00804/identifier/pubchem-compound/
dctermshttp://purl.org/dc/terms/
n30http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00804/identifier/pubchem-substance/
n14http://linked.opendata.cz/resource/drugbank/dosage/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00804/identifier/drugbank/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00804/identifier/iuphar/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00804/identifier/guide-to-pharmacology/
n11http://bio2rdf.org/drugbank:
n27http://linked.opendata.cz/resource/drugbank/drug/DB00804/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n29http://www.rxlist.com/cgi/generic/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00804/identifier/chemspider/
n9http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n19http://linked.opendata.cz/resource/drugbank/drug/DB00804/identifier/chebi/
n10http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n7http://www.drugs.com/cdi/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/resource/drugbank/drug/DB00804/identifier/wikipedia/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00804/identifier/pharmgkb/
n13http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00804
rdf:type
n3:Drug
n3:description
A muscarinic antagonist used as an antispasmodic and in urinary incontinence. It has little effect on glandular secretion or the cardiovascular system. It does have some local anesthetic properties and is used in gastrointestinal, biliary, and urinary tract spasms. [PubChem]
n3:dosage
n14:271B3F82-363D-11E5-9242-09173F13E4C5 n14:271B3F83-363D-11E5-9242-09173F13E4C5 n14:271B3F84-363D-11E5-9242-09173F13E4C5 n14:271B3F85-363D-11E5-9242-09173F13E4C5 n14:271B3F86-363D-11E5-9242-09173F13E4C5 n14:271B3F87-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:indication
For the treatment of functional bowel/irritable bowel syndrome including Colicky abdominal pain; diverticulitis
n3:manufacturer
n4:271B3F6A-363D-11E5-9242-09173F13E4C5 n4:271B3F71-363D-11E5-9242-09173F13E4C5 n4:271B3F72-363D-11E5-9242-09173F13E4C5 n4:271B3F70-363D-11E5-9242-09173F13E4C5 n4:271B3F73-363D-11E5-9242-09173F13E4C5 n4:271B3F6B-363D-11E5-9242-09173F13E4C5 n4:271B3F6E-363D-11E5-9242-09173F13E4C5 n4:271B3F6C-363D-11E5-9242-09173F13E4C5 n4:271B3F6D-363D-11E5-9242-09173F13E4C5 n4:271B3F6F-363D-11E5-9242-09173F13E4C5
owl:sameAs
n9:DB00804 n11:DB00804
dcterms:title
Dicyclomine
adms:identifier
n17:PA164744928 n18:Dicyclomine n19:4514 n20:2934 n21:50010101 n22:355 n23:355 n24:DB00804 n25:3042 n26:C06951 n27:0378-1610-01 n28:46505371
n3:mechanismOfAction
Action is achieved via a dual mechanism: (1) a specific anticholinergic effect (antimuscarinic) at the acetylcholine-receptor sites and (2) a direct effect upon smooth muscle (musculotropic).
n3:packager
n4:271B3F54-363D-11E5-9242-09173F13E4C5 n4:271B3F55-363D-11E5-9242-09173F13E4C5 n4:271B3F52-363D-11E5-9242-09173F13E4C5 n4:271B3F45-363D-11E5-9242-09173F13E4C5 n4:271B3F53-363D-11E5-9242-09173F13E4C5 n4:271B3F46-363D-11E5-9242-09173F13E4C5 n4:271B3F50-363D-11E5-9242-09173F13E4C5 n4:271B3F43-363D-11E5-9242-09173F13E4C5 n4:271B3F51-363D-11E5-9242-09173F13E4C5 n4:271B3F44-363D-11E5-9242-09173F13E4C5 n4:271B3F4E-363D-11E5-9242-09173F13E4C5 n4:271B3F4F-363D-11E5-9242-09173F13E4C5 n4:271B3F4C-363D-11E5-9242-09173F13E4C5 n4:271B3F4D-363D-11E5-9242-09173F13E4C5 n4:271B3F4A-363D-11E5-9242-09173F13E4C5 n4:271B3F4B-363D-11E5-9242-09173F13E4C5 n4:271B3F48-363D-11E5-9242-09173F13E4C5 n4:271B3F49-363D-11E5-9242-09173F13E4C5 n4:271B3F63-363D-11E5-9242-09173F13E4C5 n4:271B3F61-363D-11E5-9242-09173F13E4C5 n4:271B3F62-363D-11E5-9242-09173F13E4C5 n4:271B3F5F-363D-11E5-9242-09173F13E4C5 n4:271B3F60-363D-11E5-9242-09173F13E4C5 n4:271B3F5D-363D-11E5-9242-09173F13E4C5 n4:271B3F5E-363D-11E5-9242-09173F13E4C5 n4:271B3F58-363D-11E5-9242-09173F13E4C5 n4:271B3F59-363D-11E5-9242-09173F13E4C5 n4:271B3F3D-363D-11E5-9242-09173F13E4C5 n4:271B3F3B-363D-11E5-9242-09173F13E4C5 n4:271B3F3C-363D-11E5-9242-09173F13E4C5 n4:271B3F65-363D-11E5-9242-09173F13E4C5 n4:271B3F66-363D-11E5-9242-09173F13E4C5 n4:271B3F5C-363D-11E5-9242-09173F13E4C5 n4:271B3F64-363D-11E5-9242-09173F13E4C5 n4:271B3F5A-363D-11E5-9242-09173F13E4C5 n4:271B3F5B-363D-11E5-9242-09173F13E4C5 n4:271B3F38-363D-11E5-9242-09173F13E4C5 n4:271B3F39-363D-11E5-9242-09173F13E4C5 n4:271B3F32-363D-11E5-9242-09173F13E4C5 n4:271B3F41-363D-11E5-9242-09173F13E4C5 n4:271B3F69-363D-11E5-9242-09173F13E4C5 n4:271B3F42-363D-11E5-9242-09173F13E4C5 n4:271B3F67-363D-11E5-9242-09173F13E4C5 n4:271B3F3F-363D-11E5-9242-09173F13E4C5 n4:271B3F68-363D-11E5-9242-09173F13E4C5 n4:271B3F40-363D-11E5-9242-09173F13E4C5 n4:271B3F3E-363D-11E5-9242-09173F13E4C5 n4:271B3F3A-363D-11E5-9242-09173F13E4C5 n4:271B3F47-363D-11E5-9242-09173F13E4C5 n4:271B3F36-363D-11E5-9242-09173F13E4C5 n4:271B3F37-363D-11E5-9242-09173F13E4C5 n4:271B3F34-363D-11E5-9242-09173F13E4C5 n4:271B3F35-363D-11E5-9242-09173F13E4C5 n4:271B3F33-363D-11E5-9242-09173F13E4C5 n4:271B3F56-363D-11E5-9242-09173F13E4C5 n4:271B3F57-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
The principal route of elimination is via the urine (79.5% of the dose). Excretion also occurs in the feces, but to a lesser extent (8.4%).
n3:synonym
DICYCLOMINE Dicicloverina Dicycloverine Dicycloverin Bicyclohexyl-1-carboxylic acid 2-diethylamino-ethyl ester 2-(Diethylamino)ethyl 1-cyclohexylcyclohexanecarboxylate Dicycloverinum
n3:volumeOfDistribution
* 3.65 L/kg [20 mg oral dose]
n12:hasAHFSCode
n30:12-08-08
n3:foodInteraction
Avoid alcohol. Take this medication 30 minutes before meals.
n3:proteinBinding
>99%
n3:salt
n3:synthesisReference
Van Campen, M.G. Jr. and Tilford, C.H.; US.Patent 2,474,796; June 28, 1949; assigned to The Wm. S. Merrell Company.
foaf:page
n7:dicyclomine.html n29:dicyc.htm
n3:IUPAC-Name
n5:271B3F8C-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B3F92-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B3F91-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B3F8E-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B3F8F-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B3F90-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B3F8A-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B3F88-363D-11E5-9242-09173F13E4C5 n5:271B3F8B-363D-11E5-9242-09173F13E4C5 n5:271B3FA2-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B3F89-363D-11E5-9242-09173F13E4C5
n12:hasATCCode
n13:A03AA07
n3:H-Bond-Acceptor-Count
n5:271B3F98-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B3F99-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B3F93-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B3F94-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B3F96-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B3F95-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B3F97-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
77-19-0
n3:category
n3:containedIn
n10:271B3F7C-363D-11E5-9242-09173F13E4C5 n10:271B3F7A-363D-11E5-9242-09173F13E4C5 n10:271B3F7B-363D-11E5-9242-09173F13E4C5 n10:271B3F78-363D-11E5-9242-09173F13E4C5 n10:271B3F79-363D-11E5-9242-09173F13E4C5 n10:271B3F76-363D-11E5-9242-09173F13E4C5 n10:271B3F77-363D-11E5-9242-09173F13E4C5 n10:271B3F74-363D-11E5-9242-09173F13E4C5 n10:271B3F75-363D-11E5-9242-09173F13E4C5 n10:271B3F80-363D-11E5-9242-09173F13E4C5 n10:271B3F81-363D-11E5-9242-09173F13E4C5 n10:271B3F7E-363D-11E5-9242-09173F13E4C5 n10:271B3F7F-363D-11E5-9242-09173F13E4C5 n10:271B3F7D-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B3F9D-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B3F9F-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B3FA0-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B3FA1-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B3F9C-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B3F9B-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B3F9E-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B3F8D-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B3F9A-363D-11E5-9242-09173F13E4C5